Jaguar Animal Health (JAGX) Projected to Post Earnings on Monday

Jaguar Animal Health (NASDAQ:JAGX) is projected to announce its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($4.26) per share and revenue of $4.21 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

Jaguar Animal Health Stock Up 0.3%

Jaguar Animal Health stock opened at $0.42 on Monday. The firm has a 50 day moving average price of $0.68 and a 200-day moving average price of $1.30. The company has a quick ratio of 0.52, a current ratio of 0.81 and a debt-to-equity ratio of 4.08. Jaguar Animal Health has a twelve month low of $0.40 and a twelve month high of $15.48. The company has a market capitalization of $1.57 million, a P/E ratio of -0.01 and a beta of 0.02.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, January 22nd. Wall Street Zen lowered Jaguar Animal Health to a “strong sell” rating in a research note on Friday, January 23rd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $60.00.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.